.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Find generic sources and suppliers
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

COTELLIC Drug Profile

« Back to Dashboard

Which patents cover Cotellic, and what substitute generic drugs are available?

Cotellic is a drug marketed by Genentech Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty patent family members in twenty-eight countries.

The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this compound. Additional details are available on the cobimetinib fumarate profile page.

Summary for Tradename: COTELLIC

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list28
Clinical Trials: see list2
Patent Applications: see list36
Drug Prices:see details
DailyMed Link:COTELLIC at DailyMed

Pharmacology for Tradename: COTELLIC

Drug ClassKinase Inhibitor
Mechanism of ActionKinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc
COTELLIC
cobimetinib fumarate
TABLET;ORAL206192-001Nov 10, 2015RXYesYes8,362,002► Subscribe ► Subscribe
Genentech Inc
COTELLIC
cobimetinib fumarate
TABLET;ORAL206192-001Nov 10, 2015RXYesYes► Subscribe► Subscribe
Genentech Inc
COTELLIC
cobimetinib fumarate
TABLET;ORAL206192-001Nov 10, 2015RXYesYes7,803,839► SubscribeYY ► Subscribe
Genentech Inc
COTELLIC
cobimetinib fumarate
TABLET;ORAL206192-001Nov 10, 2015RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: COTELLIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,250Azetidines as MEK inhibitors for the treatment of proliferative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: COTELLIC

Country Document Number Estimated Expiration
Eurasian Patent Organization200801041► Subscribe
Ukraine96742► Subscribe
Israel189900► Subscribe
Hong Kong1214595► Subscribe
Luxembourg93078► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: COTELLIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
078Luxembourg► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE, Y COMPRIS LES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER HEMIFUMARATE DE COBIMETINIB; FIRST REGISTRATION DATE: 20151124
2016016Lithuania► SubscribePRODUCT NAME: KOBIMETINIBAS; REGISTRATION NO/DATE: EU/1/15/1048 20151120
0809Netherlands► SubscribePRODUCT NAME: COBIMETINIBI, DESGEWENST FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1048 20151124
2016 00021Denmark► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124
0160012 00193Estonia► SubscribePRODUCT NAME: KOBIMETINIIB;REG NO/DATE: EU/1/15/1048 24.11.2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc